Curated News
By: NewsRamp Editorial Staff
April 24, 2026
SureNano Science Advances GEP-44 Toward Clinical Trials with LabCorp
TLDR
- SureNano Science initiates IND-enabling studies for GEP-44, a GLP-1 agonist targeting obesity, potentially gaining first-mover advantage in a massive market.
- SureNano Science's GEP-44 will undergo GLP toxicology and pharmacology studies with LabCorp to assess safety and dosing before Phase I trials.
- SureNano Science advances GEP-44 to combat obesity and diabetes, aiming to improve health outcomes and quality of life for millions worldwide.
- SureNano Science explores ibogaine-based therapies for addiction, expanding its pipeline beyond metabolic disorders into neuroscience.
Impact - Why it Matters
This news matters because it signals SureNano's transition from a surfactant distributor to a serious player in the obesity and diabetes drug market, a sector valued at over $100 billion. If GEP-44 succeeds in clinical trials, it could offer a more tolerable and potentially non-injectable alternative to current GLP-1 drugs like Ozempic, expanding treatment options for millions of patients. The company's strategic partnerships also enhance its visibility, potentially driving investment and accelerating development.
Summary
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is taking a major step forward in its pharmaceutical ambitions. The company announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate, GEP-44. This critical study, to be conducted with LabCorp, is designed to assess safety, dosing parameters, and biomarkers across multiple species, supporting future Phase I clinical trials. GEP-44 is a next-generation GLP-1 agonist peptide targeting Type II diabetes and obesity, developed through SureNano's acquisition of GlucaPharm Inc. The program aims to demonstrate improved tolerability and potential non-injectable delivery, setting it apart in the crowded GLP-1 market.
Beyond its clinical pipeline, SureNano is expanding its market presence through a strategic agreement with Investor Brand Network (IBN). This partnership leverages IBN's syndication network of more than 5,000 media outlets, as detailed in the SureNano Science Ltd. press release. Additionally, SureNano is exploring early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies, signaling a broader therapeutic focus. These initiatives are intended to strengthen market awareness while supporting the continued advancement of its pipeline.
SureNano Science Ltd. is a Canadian life sciences company initially known for the sale and distribution of the SureNano™ surfactant, a food-grade compound used in nanoemulsions. However, the company is now pivoting to become a pharmaceutical-focused entity through the development of GEP-44. With the IND-enabling program underway, SureNano is positioning itself to compete in the rapidly growing obesity and metabolic disease market. The company's stock trades under the symbol SURNF on the OTCQB, and investors can find the latest news and updates at https://ibn.fm/SURNF.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SureNano Science Advances GEP-44 Toward Clinical Trials with LabCorp
